Pink army july 31
- 1. @ANDREW HESSEL JULY 31 02010 a drug company for everyone PINK ARMY COOPERATIVE
- 3. Ìý
- 4. Ìý
- 6. Ìý
- 7. COMPILE DESIGN design/build/test cycle EXECUTE TEST applications
- 9. Ìý
- 10. Ìý
- 11. Ìý
- 12. Ìý
- 13. CANCER
- 14. Ìý
- 15. Ìý
- 16. CANCER R&D IS
- 17. Ìý
- 18. Evolutionary distance ~ 4 billion years two completely different species, far removed, and bacteria are clonal
- 19. many chemical compounds have antimicrobial activity without seriously harming human cells
- 20. Ìý
- 21. Evolutionary distance max: patient’s age cancer cells are same species, only recently diverged, and every divergence is unique, cells continue to degrade over time (mixed)
- 22. Ìý
- 23. photo by billy hunt
- 24. Ìý
- 25. christa slotboom
- 26. TARGETING FAST GROWING CELLS IS SO 1950 there are plenty of normal cells that grow fast too, making treatments needlessly harsh ONE-SIZE-FITS-ALL DRUGMAKING IS ILLOGICAL each person’s DNA is different, their mutations are different, cancers are of mixed cell types CANCER RESEARCHERS DON’T MAKE DRUGS drug companies make drugs A LOT OF RESEARCH ISN’T USEFUL there appears to be a near-infinite number of paths to cancer CHANGE IS HARD cancer is industry with tremendous inertia
- 27. THE IDEAL THERAPEUTIC specific to the cancer gentle effective made quickly inexpensive
- 29. Scientists new drug X shareholders Lawyers MANUFACTURERS clinical trials Economists physicians Insurance companies geneticists
- 30. Ìý
- 31. system is inherently limited requires blockbusters unable to accelerate
- 32. RISK vs BENEFIT ( n >1) STATISTICAL ANALYSIS OF POPULATIONS requires large markets failure is expensive political slow
- 33. RISK vs BENEFIT ( n =1) no statistics – just direct observations risk benefit analysis always an individual decision ?
- 34. isolate and analyze design build test failures provide and evaluate SYNTHETIC BIOLOGY BIOFAB results COOPERATIVE data sharing
- 35. Ìý
- 36. Ìý
- 37. aims to bring together researchers, developers, cancer sufferers and supporters in a self-funded, open-source therapeutic venture
- 38. goal: not a new drug, but a completely new way of making drugs one that can accelerate and improve over time
- 39. a significant step towards faster, better, cheaper cancer drugs + =
- 40. diagnostics today, treatments tomorrow